Refraction following PRK stable over eight years

Article

Postoperative refraction following photorefractive keratectomy (PRK) remains stable from the second year postoperatively through to eight years.

Postoperative refraction following photorefractive keratectomy (PRK) remains stable from the second year postoperatively through to eight years, according to Hossein Mohammad Rabei and colleagues from the Basir Eye Center, Tehran, Iran.

The researchers obtained data from 2,141 myopic patients who underwent PRK with single-step method using a NIDEK EC-5000 excimer laser with 5-6 mm ablation zones in Basir Eye Center, Tehran during 1994-1996.

A total of 179 myopic eyes of 98 patients who had undergone PRK and completed eight years follow-up were included in the study. Follow-up examinations were performed one, three, six and 12 months and two and eight years after surgery. The treated eyes were divided into three groups according to preoperative refraction: low myopes, medium myopes and high myopes.

After eight years follow-up, the percentage of eyes within ±1 D of emmetropia was 69.1%, 30% and 46.2% in the low, medium and high groups, respectively. Changes in myopic regression stabilized in all myopic groups within two years and was significantly correlated to preoperative spherical equivalent refraction. Corneal haze was recorded in 5% but cleared within two years in 89% of cases.

The results of this long-term study demonstrate that refraction following PRK does remain stable for up to eight years following surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.